References
- Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011;469:343–349.
- Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17:2613–2618.
- Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181–185.
- Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013;23:677–692.
- Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013;121:4512–4520.
- Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012;18:298–301.
- Shi M, Shahsafaei A, Liu C, et al. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leuk Lymphoma 2015;56:2087–2091.
- Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112:4202–4212.
- Coiffier B, Federico M, Caballero D, et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev 2014;40:1080–1088.
- Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890–896.
- McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108–112.
- Copeland RA. Activity of the EZH2 inhibitor EPZ-6438 (E7438) in non-Hodgkin lymphoma: preclinical models and early clinical observations. Presented at: ASH Meeting on Lymphoma Biology, 10–13 August 2014, Colorado Springs, CO, USA: Abstract 67.